Table 3.
The association between the serum LAG-3 and PD-L1 level with clinical characteristics of HCC patients.
| Variable | LAG-3 | PD-L1 | ||||
|---|---|---|---|---|---|---|
| Low | High | P | Low | High | P | |
| Patients | 60 | 40 | 82 | 18 | ||
| Age(years) | 0.927 | 0.707 | ||||
| ≤ 50 | 16 | 11 | 21 | 6 | ||
| > 50 | 44 | 29 | 61 | 12 | ||
| Gender | 0.724 | 1.000 | ||||
| Female | 9 | 5 | 11 | 3 | ||
| Male | 51 | 35 | 71 | 15 | ||
| HbsAg | 0.158 | 0.444 | ||||
| Negative | 6 | 8 | 13 | 1 | ||
| Positive | 54 | 32 | 69 | 17 | ||
| Cirrhosis | 0.034 | 0.988 | ||||
| No | 12 | 2 | 12 | 2 | ||
| Yes | 48 | 38 | 70 | 16 | ||
| Portal vein invasion | 0.161 | 0.893 | ||||
| Absent | 44 | 24 | 56 | 12 | ||
| Present | 16 | 16 | 26 | 6 | ||
| Tumor size, cm | 0.187 | 0.697 | ||||
| ≤5 | 29 | 14 | 36 | 7 | ||
| >5 | 31 | 26 | 46 | 11 | ||
| Tumor number | 0.934 | 0.817 | ||||
| Single | 25 | 17 | 34 | 8 | ||
| Multiple | 35 | 23 | 48 | 10 | ||
| AFP(ng/ml) | 0.146 | 0.578 | ||||
| ≤20 | 20 | 8 | 22 | 6 | ||
| >20 | 40 | 32 | 60 | 12 | ||
| Pre-TACE TB,μmol/L | 0.373 | 0.012 | ||||
| ≤10.4 | 20 | 10 | 29 | 1 | ||
| >10.4 | 40 | 30 | 53 | 17 | ||
| Pre-TACE ALT,U/L | 0.029 | 0.578 | ||||
| ≤55.5 | 48 | 24 | 60 | 12 | ||
| >55.5 | 12 | 16 | 22 | 6 | ||
| Pre-TACE AST,U/L | 0.020 | 0.166 | ||||
| ≤48.5 | 41 | 18 | 51 | 8 | ||
| >48.5 | 19 | 22 | 31 | 10 | ||
| BCLC stage | 0.017 | 0.958 | ||||
| 0+A | 16 | 3 | 15 | 4 | ||
| B+C | 44 | 37 | 67 | 14 | ||
HBsAg, hepatitis B surface antigen; AFP, αfetoprotein; TBiL, total bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BCLC, Barcelona Clinic Liver Cancer. P < 0.05 was considered statistically significant.